Rose Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
Rose Capital Advisors's PFE Position: Q3 2026 in Review
Rose Capital Advisors reduced its Pfizer (PFE) stake by 13% in Q3 2026, selling an estimated $130K and leaving 32,688 shares worth $932K. The position accounts for 0.23% of the portfolio, ranked #87.
Rose Capital Advisors first reported a position in PFE in Q2 2026 and has held it in 2 quarters since. 2,916 funds tracked by Wall St. Rank hold PFE as of Q3 2026.
- Rose Capital Advisors held 32,688 shares of Pfizer worth $932K as of Q3 2026.
- Rose Capital Advisors sold 4,892 Pfizer shares in Q3 2026, an estimated $130K.
- Pfizer made up 0.23% of Rose Capital Advisors's portfolio in Q3 2026, its #87 holding.
- Rose Capital Advisors first reported a position in Pfizer in Q2 2026 and has held it in 2 quarters since.
- 2,916 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.
Based on Rose Capital Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.